Joel Greenblatt's ABBV Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 48,471 shares of AbbVie Inc. (ABBV) worth $11.22 M, representing 0.05% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2015, adding 546,464 shares. Largest reduction occurred in Q2 2015, reducing 521,618 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +101,754 | Add 0.00% | 101,753 | $41.34 |
| Q3 2013 | +40,201 | Add 39.51% | 141,954 | $44.73 |
| Q4 2013 | -37,973 | Reduce 26.75% | 103,981 | $52.81 |
| Q1 2014 | +125,168 | Add 120.38% | 229,149 | $51.40 |
| Q2 2014 | -140,226 | Reduce 61.19% | 88,923 | $56.44 |
| Q3 2014 | -79,463 | Reduce 89.36% | 9,460 | $57.72 |
| Q4 2014 | -701 | Reduce 7.41% | 8,759 | $65.42 |
| Q1 2015 | +546,464 | Add 6238.89% | 555,223 | $58.54 |
| Q2 2015 | -521,618 | Reduce 93.95% | 33,605 | $67.19 |
| Q3 2015 | +39,432 | Add 117.34% | 73,037 | $54.41 |
| Q4 2015 | +131,134 | Add 179.54% | 204,171 | $59.24 |
| Q1 2016 | +441,664 | Add 216.32% | 645,835 | $57.12 |
| Q2 2016 | +259,763 | Add 40.22% | 905,598 | $61.91 |
| Q3 2016 | -221,242 | Reduce 24.43% | 684,356 | $63.07 |
| Q4 2016 | +251,081 | Add 36.69% | 935,437 | $62.62 |
| Q1 2017 | -316,957 | Reduce 33.88% | 618,480 | $65.16 |
| Q2 2017 | -320,812 | Reduce 51.87% | 297,668 | $72.51 |
| Q3 2017 | +101,169 | Add 33.99% | 398,837 | $88.86 |
| Q4 2017 | -159,593 | Reduce 40.01% | 239,244 | $96.71 |
| Q1 2018 | +205,570 | Add 85.92% | 444,814 | $94.65 |
| Q2 2018 | -55,015 | Reduce 12.37% | 389,799 | $92.65 |
| Q3 2018 | -63,563 | Reduce 16.31% | 326,236 | $94.58 |
| Q4 2018 | -22,979 | Reduce 7.04% | 303,257 | $92.19 |
| Q1 2019 | +63,196 | Add 20.84% | 366,453 | $80.59 |
| Q2 2019 | +42,056 | Add 11.48% | 408,509 | $72.72 |
| Q3 2019 | -190,784 | Reduce 46.70% | 217,725 | $75.72 |
| Q4 2019 | -32,101 | Reduce 14.74% | 185,624 | $88.54 |
| Q1 2020 | -53,384 | Reduce 28.76% | 132,240 | $76.19 |
| Q2 2020 | +67,425 | Add 50.99% | 199,665 | $98.18 |
| Q3 2020 | -164,931 | Reduce 82.60% | 34,734 | $87.58 |
| Q4 2020 | +25,174 | Add 72.48% | 59,908 | $107.15 |
| Q1 2021 | +8,006 | Add 13.36% | 67,914 | $108.23 |
| Q2 2021 | -10,187 | Reduce 15.00% | 57,727 | $112.63 |
| Q3 2021 | +47,567 | Add 82.40% | 105,294 | $107.87 |
| Q4 2021 | -48,702 | Reduce 46.25% | 56,592 | $135.41 |
| Q1 2022 | -8,962 | Reduce 15.84% | 47,630 | $162.10 |
| Q2 2022 | +4,608 | Add 9.67% | 52,238 | $153.16 |
| Q3 2022 | +1,688 | Add 3.23% | 53,926 | $134.20 |
| Q4 2022 | -21,934 | Reduce 40.67% | 31,992 | $161.61 |
| Q1 2023 | -5,706 | Reduce 17.84% | 26,286 | $159.37 |
| Q2 2023 | +28,499 | Add 108.42% | 54,785 | $134.73 |
| Q3 2023 | +18,800 | Add 34.32% | 73,585 | $149.06 |
| Q4 2023 | -29,168 | Reduce 39.64% | 44,417 | $154.97 |
| Q1 2024 | +17,166 | Add 38.65% | 61,583 | $182.10 |
| Q2 2024 | -15,501 | Reduce 25.17% | 46,082 | $171.52 |
| Q3 2024 | -390 | Reduce 0.85% | 45,692 | $197.48 |
| Q4 2024 | -17,305 | Reduce 37.87% | 28,387 | $177.70 |
| Q1 2025 | +4,105 | Add 14.46% | 32,492 | $209.52 |
| Q2 2025 | +4,281 | Add 13.18% | 36,773 | $185.62 |
| Q3 2025 | +11,698 | Add 31.81% | 48,471 | $231.54 |
Joel Greenblatt's AbbVie Investment FAQs
Joel Greenblatt first purchased AbbVie Inc. (ABBV) in Q2 2013, acquiring 101,753 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held AbbVie Inc. (ABBV) for 50 quarters since Q2 2013.
Joel Greenblatt's largest addition to AbbVie Inc. (ABBV) was in Q1 2015, adding 555,223 shares worth $32.5 M.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 48,471 shares of AbbVie Inc. (ABBV), valued at approximately $11.22 M.
As of the Q3 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.05% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in AbbVie Inc. (ABBV) was 935,437 shares, as reported at the end of Q4 2016.